Window of opportunity with abatacept in Rheumatoid arthritis-associated interstitial lung disease: A multicentre study of 526 patients - PubMed
5 hours ago
- #Observational study
- #Abatacept
- #Rheumatoid arthritis-associated interstitial lung disease
- Abatacept stabilized lung function in RA-ILD patients, with 77% showing FVC improvement/stabilization and 72% DLCO improvement/stabilization.
- Early initiation (within 6 months) vs late (≥24 months) showed no significant difference in FVC or DLCO outcomes, but each month delay was linked to greater DLCO decline.
- Abatacept improved RA control (reduced DAS28-ESR) and glucocorticoid use, with 83% drug retention and a favorable safety profile.